Latest Breaking News On - Device agency - Page 4 : vimarsana.com

Partner Therapeutics Leukine® (sargramostim) Receives Approval in Japan to Treat Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Partner Therapeutics Leukine® (sargramostim) Receives Approval in Japan to Treat Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesRobert mulroyNobelpharma coInnovation of niigata university medical dental hospitalDevice agencyJapanese pharmaceuticalsDivision of pioneering advanced therapeuticsTanner pharma groupNiigata universityPartner therapeutics incPrnewswire partner therapeutics incTrade nameMedical device agencyProject professorPioneering advanced therapeuticsMedical innovation

Partner Therapeutics Leukine® (sargramostim) Receives Approval in Japan to Treat Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

/PRNewswire/ Partner Therapeutics, Inc. (PTx) announced that its partner Nobelpharma received approval from the Japanese Pharmaceuticals and Medical Device.

United statesRobert mulroyDevice agencyInnovation of niigata university medical dental hospitalJapanese pharmaceuticalsTanner pharma groupDivision of pioneering advanced therapeuticsNobelpharma coNiigata universityPrnewswire partner therapeutics incTrade nameMedical device agencySponsor investigator koh nakataProject professorPioneering advanced therapeuticsMedical innovation

Partner Therapeutics Leukine® (sargramostim) Receives Approval in Japan to Treat Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

United statesRobert mulroyTanner pharma groupNiigata universityDivision of pioneering advanced therapeuticsPrnewswire partner therapeutics incNobelpharma coJapanese pharmaceuticalsDevice agencyPartner therapeutics incInnovation of niigata university medical dental hospitalTrade nameMedical device agencyProject professorPioneering advanced therapeuticsMedical innovation

BioCardia, Inc (NASDAQ:BCDA) Q4 2023 Earnings Call Transcript

BioCardia, Inc. beats earnings expectations. Reported EPS is $-0.09, expectations were $-0.11.

United statesDavid mcclungPeter altmanBrent pearsonJoe smithMiranda petoLargest airport companiesSam clubDevice agencyBiocardia incCall transcript marchEnd financial resultsBusiness update conferenceBiocardia investorChief executive officerChief financial

BioCardia : Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results -March 27, 2024 at 01:30 pm EDT

BioCardia Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results March 27, 2024 BioCardia®, Inc. [Nasdaq: BCDA], a developer of.

United statesFinkelstein schoenfeldPeter altmanDevice agencyMedicaid servicesExchange commission onBiocardia incMaryland stem cell research fundExchange commissionBiocardia reports fourth quarterFull yearFinancial resultsMorph access innovationsAutologous cell therapyTherapy heart failureHeart failure therapy